59P: Evaluating the effectiveness of amivantamab plus lazertinib in CHRYSALIS-2 vs EGFR TKI monotherapy in a matched real-world cohort of participants with atypical EGFR-mutated advanced NSCLC

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI:10.1016/S1556-0864(25)00254-0

P. Tomasini , Y. Wang , S-H. Lee , J. Cui , E. Felip , A. Spira , Y. Li , L. Wu , S. Michels , E. Ichihara , J. Neal , L. Demirdjian , C.S. Meyer , Y. Zhang , H. Kanakamedala , A. Louder , L. Trani , I. Leconte , M. Baig , B.C. Cho

引用次数: 0

查看原文本刊更多论文

59P：在非典型EGFR突变晚期NSCLC患者的匹配现实世界队列中，评估amivantamab + lazertinib在CHRYSALIS-2与EGFR TKI单药治疗中的有效性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.